|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
1,770,000,000 |
Market
Cap: |
291.27(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$132.51 - $182.1 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 560 |
Guru Rank Value : 3 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile AbbVie is a research-based biopharmaceutical company. Co. operates as a single business segment dedicated to the research and development, manufacturing, commercialization and sale of medicines and therapies. Co.'s products include: immunology products such as Humira, Skyrizi, and Rinvoq; oncology products such as Imbruvica and Venclexta/Venclyxto; aesthetics products such as Botox Cosmetic and Juvederm Collection; neuroscience products such as Botox Therapeutic, Vraylar, and Ubrelvy; eyecare products such as Lumigan/Ganfort, Alphagan/Combigan, and Restasis; women's health products such as Lo Loestrin and Orilissa/Oriahnn; and other key products such as Creon, Lupron, and Synthroid.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
459,004 |
461,916 |
540,416 |
911,397 |
Total Sell Value |
$81,195,771 |
$81,646,316 |
$93,320,391 |
$150,495,349 |
Total People Sold |
9 |
9 |
9 |
13 |
Total Sell Transactions |
10 |
11 |
13 |
30 |
End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sorg Elaine K. |
SVP, US COMMERCIAL OPERATIONS |
|
2023-03-01 |
4 |
S |
$155.00 |
$2,325,465 |
D/D |
(15,003) |
42,829 |
|
13% |
|
Sorg Elaine K. |
SVP, US COMMERCIAL OPERATIONS |
|
2023-03-01 |
4 |
OE |
$93.50 |
$1,402,781 |
D/D |
15,003 |
57,832 |
|
- |
|
Gonzalez Richard A |
CHAIRMAN OF THE BOARD AND CEO |
|
2023-02-28 |
4 |
D |
$154.28 |
$17,558,607 |
D/D |
(113,810) |
646,344 |
|
- |
|
Michael Robert A. |
VICE CHAIRMAN |
|
2023-02-28 |
4 |
D |
$154.28 |
$7,457,124 |
D/D |
(48,335) |
98,645 |
|
- |
|
Richmond Timothy J. |
EVP, CHIEF HR OFFICER |
|
2023-02-28 |
4 |
D |
$154.28 |
$5,416,925 |
D/D |
(35,111) |
57,978 |
|
- |
|
Stewart Jeffrey Ryan |
EVP, COMMERCIAL OPERATIONS |
|
2023-02-28 |
4 |
D |
$154.28 |
$3,843,115 |
D/D |
(24,910) |
92,256 |
|
- |
|
Strom Carrie C |
SVP & PRES GLOBAL ALLERG AESTH |
|
2023-02-28 |
4 |
D |
$154.28 |
$888,961 |
D/D |
(5,762) |
32,159 |
|
- |
|
Durkin Brian L |
VP, CONTROLLER |
|
2023-02-28 |
4 |
D |
$154.28 |
$1,725,159 |
D/D |
(11,182) |
33,149 |
|
- |
|
Reents Scott T |
EVP, CHIEF FINANCIAL OFFICER |
|
2023-02-28 |
4 |
D |
$154.28 |
$1,956,733 |
D/D |
(12,683) |
16,751 |
|
- |
|
Siatis Perry C |
EVP, GC AND SECRETARY |
|
2023-02-28 |
4 |
D |
$154.28 |
$1,489,728 |
D/D |
(9,656) |
22,512 |
|
- |
|
Saleki-Gerhardt Azita |
EVP, OPERATIONS |
|
2023-02-28 |
4 |
D |
$154.28 |
$5,146,627 |
D/D |
(33,359) |
199,849 |
|
- |
|
Hudson Thomas J |
SVP, R&D AND CSO |
|
2023-02-28 |
4 |
D |
$154.28 |
$4,307,806 |
D/D |
(27,922) |
81,329 |
|
- |
|
Sorg Elaine K. |
SVP, US COMMERCIAL OPERATIONS |
|
2023-02-28 |
4 |
D |
$154.28 |
$3,062,458 |
D/D |
(19,850) |
42,829 |
|
- |
|
Siatis Perry C |
EVP, GC AND SECRETARY |
|
2023-02-21 |
4 |
S |
$150.73 |
$1,112,178 |
D/D |
(7,364) |
32,168 |
|
11% |
|
Siatis Perry C |
EVP, GC AND SECRETARY |
|
2023-02-21 |
4 |
OE |
$93.50 |
$688,534 |
D/D |
7,364 |
39,532 |
|
- |
|
Strom Carrie C |
SVP & PRES GLOBAL ALLERG AESTH |
|
2023-02-21 |
4 |
S |
$150.71 |
$4,310,771 |
D/D |
(28,541) |
37,921 |
|
11% |
|
Strom Carrie C |
SVP & PRES GLOBAL ALLERG AESTH |
|
2023-02-21 |
4 |
OE |
$56.93 |
$872,949 |
D/D |
14,179 |
66,462 |
|
- |
|
Sorg Elaine K. |
SVP, US COMMERCIAL OPERATIONS |
|
2023-02-21 |
4 |
S |
$150.74 |
$2,314,119 |
D/D |
(15,321) |
62,679 |
|
11% |
|
Sorg Elaine K. |
SVP, US COMMERCIAL OPERATIONS |
|
2023-02-21 |
4 |
OE |
$105.92 |
$1,622,800 |
D/D |
15,321 |
78,000 |
|
- |
|
Austin Roxanne S |
|
|
2023-02-17 |
4/A |
S |
$150.50 |
$936,411 |
D/D |
(6,222) |
34,483 |
|
- |
|
Saleki-Gerhardt Azita |
EVP, OPERATIONS |
|
2023-02-17 |
4 |
S |
$149.13 |
$3,738,144 |
D/D |
(25,000) |
233,208 |
|
12% |
|
Saleki-Gerhardt Azita |
EVP, OPERATIONS |
|
2023-02-17 |
4 |
OE |
$51.42 |
$1,285,500 |
D/D |
25,000 |
258,208 |
|
- |
|
Austin Roxanne S |
|
|
2023-02-17 |
4 |
S |
$150.50 |
$1,505,000 |
D/D |
(10,000) |
40,705 |
|
12% |
|
Reents Scott T |
EVP, CHIEF FINANCIAL OFFICER |
|
2023-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
28,625 |
29,434 |
|
- |
|
Stewart Jeffrey Ryan |
EVP, COMMERCIAL OPERATIONS |
|
2023-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
56,225 |
117,166 |
|
- |
|
641 Records found
|
|
Page 4 of 26 |
|
|